Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19

Am J Ophthalmol. 2020 Aug:216:A5-A6. doi: 10.1016/j.ajo.2020.04.028. Epub 2020 May 26.

Authors

Scott W McPherson¹, Jan E Keunen², Alan C Bird³, Emily Y Chew⁴, Frederik J van Kuijk⁵

Affiliations

¹ Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.
² Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
³ Moorfields Eye Hospital, London, United Kingdom.
⁴ Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
⁵ Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: vankuijk@umn.edu.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Angiotensin-Converting Enzyme 2
Antiviral Agents / administration & dosage
Betacoronavirus / drug effects*
COVID-19
Clinical Trials as Topic
Coronavirus Infections / prevention & control*
Enzyme Inhibitors / administration & dosage
Humans
Pandemics / prevention & control*
Peptidyl-Dipeptidase A / drug effects
Pneumonia, Viral / prevention & control*
SARS-CoV-2
Zinc Compounds / administration & dosage*

Substances

Antiviral Agents
Enzyme Inhibitors
Zinc Compounds
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2

Grants and funding

P30 EY011374/EY/NEI NIH HHS/United States